Media headlines about Rosetta Genomics (NASDAQ:ROSG) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rosetta Genomics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 44.9912676838996 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Rosetta Genomics stock traded down $0.04 on Tuesday, hitting $0.35. The stock had a trading volume of 124,209 shares, compared to its average volume of 133,021. Rosetta Genomics has a 52-week low of $0.23 and a 52-week high of $3.29.
ROSG has been the subject of several recent analyst reports. ValuEngine raised Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barrington Research lowered Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests.
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.